Promising updated data in NEPC at #ESMO26

Deborah Mukherji· @dmukherji · X·2026-10-23 19:46· 2 days agoScore90

Body · original

In KEYNOTE-365, pembrolizumab + carboplatin/etoposide showed higher ORR, longer rPFS and OS (10.2 vs 7.1 mo) vs chemotherapy alone #GunhildVonAmsberg @OncoAlert

279 views · 10 likes · 6 reposts · 0 replies

Conference abstracts

2217RONCT04746300matched by Rapid oral: Genitourinary tumours, prostate, penile and testis

Updated results from the phase 1b/2 KEYNOTE-365 cohort I: Pembrolizumab (pembro) + carboplatin and etoposide chemotherapy (chemo) or chemo alone for neuroendocrine prostate cancer (NEPC)

https://esmocongress.esmo.org

Source: Deborah Mukherji · x.com